aspartic acid has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 14 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment of pediatric acute lymphoblastic leukemia (ALL) with pegaspargase exploits ALL cells dependency on asparagine." | 1.62 | Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia. ( Bielawski, JP; Cohen, A; Connors, J; Dunn, KA; Forbrigger, Z; Kulkarni, K; Langille, MGI; MacDonald, T; Penny, SL; Rahman, M; Stadnyk, AW; Van Limbergen, J, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Muneer, F | 1 |
Siddique, MH | 1 |
Azeem, F | 1 |
Rasul, I | 1 |
Muzammil, S | 1 |
Zubair, M | 1 |
Afzal, M | 1 |
Nadeem, H | 1 |
Dunn, KA | 1 |
Forbrigger, Z | 1 |
Connors, J | 1 |
Rahman, M | 1 |
Cohen, A | 1 |
Van Limbergen, J | 1 |
Langille, MGI | 1 |
Stadnyk, AW | 1 |
Bielawski, JP | 1 |
Penny, SL | 1 |
MacDonald, T | 1 |
Kulkarni, K | 1 |
Zuo, S | 1 |
Zhang, T | 1 |
Jiang, B | 1 |
Mu, W | 1 |
Nath, CE | 1 |
Dallapozza, L | 1 |
Eslick, AE | 1 |
Misra, A | 1 |
Carr, D | 1 |
Earl, JW | 1 |
Ficek, K | 1 |
Blamek, S | 1 |
Syguła, D | 1 |
Miszczyk, L | 1 |
Sońta-Jakimczyk, D | 1 |
Tarnawski, R | 1 |
Chen, SH | 1 |
Yang, W | 1 |
Fan, Y | 1 |
Stocco, G | 1 |
Crews, KR | 1 |
Yang, JJ | 1 |
Paugh, SW | 1 |
Pui, CH | 1 |
Evans, WE | 1 |
Relling, MV | 1 |
Aslan, H | 1 |
Donmez, FY | 1 |
Hekimoglu, OK | 1 |
Tore, HG | 1 |
Saarinen-Pihkala, UM | 1 |
Parto, K | 1 |
Riikonen, P | 1 |
Lähteenmäki, PM | 1 |
Békàssy, AN | 1 |
Glomstein, A | 1 |
Möttönen, M | 1 |
Steiner, M | 1 |
Hochreiter, D | 1 |
Kasper, DC | 1 |
Kornmüller, R | 1 |
Pichler, H | 1 |
Haas, OA | 1 |
Pötschger, U | 1 |
Hutter, C | 1 |
Dworzak, MN | 1 |
Mann, G | 1 |
Attarbaschi, A | 1 |
Holownia, A | 1 |
Trofimiuk, E | 1 |
Krawczuk-Rybak, M | 1 |
Jakubow, P | 1 |
Kaliszewski, J | 1 |
Muszynska-Roslan, K | 1 |
Braszko, JJ | 1 |
Parr, IB | 1 |
Boehlein, SK | 1 |
Dribben, AB | 1 |
Schuster, SM | 1 |
Richards, NG | 1 |
Boos, J | 1 |
Werber, G | 1 |
Ahlke, E | 1 |
Schulze-Westhoff, P | 1 |
Nowak-Göttl, U | 1 |
Würthwein, G | 1 |
Verspohl, EJ | 1 |
Ritter, J | 1 |
Jürgens, H | 1 |
Chan, YL | 1 |
Roebuck, DJ | 1 |
Yuen, MP | 1 |
Yeung, KW | 1 |
Lau, KY | 1 |
Li, CK | 1 |
Chik, KW | 1 |
Aslanian, AM | 1 |
Kilberg, MS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
2157GCCC: A Phase I Trial of Calaspargase Pegol-mknl in Combination With High Dose Cytarabine and Idarubicin in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia[NCT04953780] | Phase 1 | 24 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
Intervention | Percent change (Mean) |
---|---|
4 hr | -44 |
24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
Intervention | Percentage of participants (Number) |
---|---|
Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
Intervention | pmol/1,000,000,000 cells (Mean) |
---|---|
4 hr | 1688 |
24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
Intervention | Percentage of Participants (Number) |
---|---|
Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
Intervention | arbitrary units (Median) | |
---|---|---|
Prednisolone-sensitive cells | Prednisolone-resistant cells | |
Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
Intervention | participants (Number) | |
---|---|---|
Negative <0.01% | Positive >= 0.01% | |
Total Therapy | 390 | 102 |
2 reviews available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
Microbial L-asparaginase: purification, characterization and applications.
Topics: Ammonia; Asparaginase; Asparagine; Aspartic Acid; Bacteria; Fungi; Hodgkin Disease; Humans; Phylogen | 2020 |
Recent research progress on microbial L-asparaginases.
Topics: Acrylamide; Asparaginase; Asparagine; Aspartic Acid; Bacteria; Fungi; Humans; Hydrolysis; Precursor | 2015 |
1 trial available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; Child; Child | 2012 |
11 other studies available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma
Article | Year |
---|---|
Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Genes, Bacterial; Glutamic Ac | 2021 |
An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Child, Preschool; | 2009 |
Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy.
Topics: Adolescent; Aspartic Acid; Brain Injuries; Case-Control Studies; Child; Child, Preschool; Choline; C | 2010 |
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
Topics: Antineoplastic Agents; Asparaginase; Aspartic Acid; Cell Line; Genome-Wide Association Study; Humans | 2011 |
The magnetic resonance spectroscopy findings of extrapontine myelinolysis in a patient with acute lymphoblastic leukemia.
Topics: Aspartic Acid; Choline; Creatine; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spe | 2012 |
Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; A | 2012 |
Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Child; Daunorubicin; Ex | 2004 |
Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs.
Topics: Alkylation; Antineoplastic Agents; Asparagine; Aspartate-Ammonia Ligase; Aspartic Acid; Bacterial Pr | 1996 |
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Child, Preschool; | 1996 |
Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy in patients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Aspartic Acid; Brain; Brain Infarction; Cerebrov | 2001 |
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
Topics: Amino Acids; Asparaginase; Aspartate-Ammonia Ligase; Aspartic Acid; Biological Transport; Cell Divis | 2001 |